~~<i id='096EBB02F5'><strike id='096EBB02F5'><tt id='096EBB02F5'><pre id='096EBB02F5'></pre></tt></strike></i>~~

Home» knowledge» comprehensive

comprehensive

author：explore 2025-09-28 11:03:06 Page View：6899

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bacterial infection may be ‘key event’ in endometriosis, study says
Next article： In age of alternative facts, a scholarly course on calling out crap

focus

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

Grail is spending more than ever lobbying Congress

GrailGrailspentmorethan$1millionlastquarterlobbyingCongress,underscoringtheurgencyofthecompany’sbidt

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

U.K. decision on ALS drug has neurologists, advocates up in arms

TheALSdrugtofersenismarketedasQalsodyintheU.S.BiogenLONDON—Neurologistsandpatientadvocatesareupinarm